AU2005256470B2 - Novel compounds - Google Patents

Novel compounds Download PDF

Info

Publication number
AU2005256470B2
AU2005256470B2 AU2005256470A AU2005256470A AU2005256470B2 AU 2005256470 B2 AU2005256470 B2 AU 2005256470B2 AU 2005256470 A AU2005256470 A AU 2005256470A AU 2005256470 A AU2005256470 A AU 2005256470A AU 2005256470 B2 AU2005256470 B2 AU 2005256470B2
Authority
AU
Australia
Prior art keywords
dimethyl
formula
compounds
inden
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005256470A
Other languages
English (en)
Other versions
AU2005256470A1 (en
Inventor
Alan David Borthwick
Deirdre Mary Bernadette Hickey
John Liddle
Andrew Mcmurtrie Mason
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32800053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005256470(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU2005256470A1 publication Critical patent/AU2005256470A1/en
Application granted granted Critical
Publication of AU2005256470B2 publication Critical patent/AU2005256470B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AU2005256470A 2004-06-23 2005-06-21 Novel compounds Ceased AU2005256470B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0414093.5A GB0414093D0 (en) 2004-06-23 2004-06-23 Novel compounds
GB0414093.5 2004-06-23
PCT/EP2005/006760 WO2006000399A1 (en) 2004-06-23 2005-06-21 Novel compounds

Publications (2)

Publication Number Publication Date
AU2005256470A1 AU2005256470A1 (en) 2006-01-05
AU2005256470B2 true AU2005256470B2 (en) 2012-02-02

Family

ID=32800053

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005256470A Ceased AU2005256470B2 (en) 2004-06-23 2005-06-21 Novel compounds

Country Status (30)

Country Link
US (9) US7550462B2 (cg-RX-API-DMAC10.html)
EP (2) EP1758886B1 (cg-RX-API-DMAC10.html)
JP (2) JP5405019B2 (cg-RX-API-DMAC10.html)
KR (1) KR101186447B1 (cg-RX-API-DMAC10.html)
CN (1) CN1972924B (cg-RX-API-DMAC10.html)
AR (1) AR049405A1 (cg-RX-API-DMAC10.html)
AU (1) AU2005256470B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0512376A (cg-RX-API-DMAC10.html)
CA (1) CA2571527C (cg-RX-API-DMAC10.html)
CY (1) CY1116183T1 (cg-RX-API-DMAC10.html)
DK (1) DK1758886T3 (cg-RX-API-DMAC10.html)
ES (1) ES2537801T3 (cg-RX-API-DMAC10.html)
GB (1) GB0414093D0 (cg-RX-API-DMAC10.html)
HK (1) HK1208669A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20150401T1 (cg-RX-API-DMAC10.html)
HU (1) HUE025869T2 (cg-RX-API-DMAC10.html)
IL (2) IL179905A0 (cg-RX-API-DMAC10.html)
MA (1) MA28675B1 (cg-RX-API-DMAC10.html)
MX (1) MXPA06014545A (cg-RX-API-DMAC10.html)
MY (1) MY143578A (cg-RX-API-DMAC10.html)
NO (1) NO338769B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ551733A (cg-RX-API-DMAC10.html)
PE (1) PE20060477A1 (cg-RX-API-DMAC10.html)
PL (1) PL1758886T3 (cg-RX-API-DMAC10.html)
PT (1) PT1758886E (cg-RX-API-DMAC10.html)
RU (1) RU2382038C2 (cg-RX-API-DMAC10.html)
SI (1) SI1758886T1 (cg-RX-API-DMAC10.html)
TW (1) TWI348466B (cg-RX-API-DMAC10.html)
WO (1) WO2006000399A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200610022B (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
EP1572950B1 (en) 2002-06-17 2012-10-10 Thrasos, Inc. Single domain tdf-related compounds and analogs thereof
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
US8299212B2 (en) 2005-09-20 2012-10-30 Thrasos Therapeutics, Inc. TDF-related compounds and analogs thereof, analogs and bioactive fragments
JP2013509391A (ja) * 2009-10-30 2013-03-14 グラクソ グループ リミテッド （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態
SG10202009723PA (en) 2016-01-04 2020-11-27 ObsEva SA Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
WO2017203012A1 (en) * 2016-05-27 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Epelsiban for use in the treatment of adenomyosis
WO2018015497A2 (en) 2016-07-21 2018-01-25 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
WO2019230647A1 (ja) * 2018-05-29 2019-12-05 花王株式会社 シートの快感情喚起性能の評価方法及び快感情喚起シート
AU2019366366B2 (en) 2018-10-22 2025-09-25 William D. Carlson Therapeutic combinations of TDFRPs and additional agents and methods of use
US20220323410A1 (en) 2019-09-03 2022-10-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh) 2020-02-10 2022-11-22 奥布赛瓦股份公司 用于催产素受体拮抗剂疗法的生物标志物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
WO2003053443A1 (en) * 2001-12-21 2003-07-03 Glaxo Group Limited Substituted diketopiperazines as oxytocin antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
DE3830096A1 (de) 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
US5464788A (en) 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
YU47600A (sh) 1998-01-27 2002-09-19 Aventis Pharmaceuticals Products Inc. SUPSTITUISANI OKSOAZAHETEROCIKLIL INHIBITORI FAKTORA Xa
EP1051397B1 (en) 1998-01-29 2008-12-31 Aventis Pharmaceuticals Inc. Method for preparing an n- (aliphatic or aromatic)carbonyl -2-aminoacetamide compound and a cyclyzed compound
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
WO2003053443A1 (en) * 2001-12-21 2003-07-03 Glaxo Group Limited Substituted diketopiperazines as oxytocin antagonists

Also Published As

Publication number Publication date
HUE025869T2 (en) 2016-05-30
IL237513A0 (en) 2015-04-30
KR20070031953A (ko) 2007-03-20
AR049405A1 (es) 2006-07-26
PT1758886E (pt) 2015-04-22
RU2007102274A (ru) 2008-07-27
US7550462B2 (en) 2009-06-23
TW200616636A (en) 2006-06-01
US20130253188A1 (en) 2013-09-26
US20100305127A1 (en) 2010-12-02
JP2013010790A (ja) 2013-01-17
EP1758886B1 (en) 2015-03-04
ES2537801T3 (es) 2015-06-12
MY143578A (en) 2011-05-31
JP5405019B2 (ja) 2014-02-05
HRP20150401T1 (hr) 2015-05-08
NZ551733A (en) 2010-06-25
US7919492B2 (en) 2011-04-05
US20090247541A1 (en) 2009-10-01
TWI348466B (en) 2011-09-11
NO20070173L (no) 2007-01-22
JP2008503534A (ja) 2008-02-07
CN1972924A (zh) 2007-05-30
WO2006000399A1 (en) 2006-01-05
CY1116183T1 (el) 2017-02-08
KR101186447B1 (ko) 2012-09-27
RU2382038C2 (ru) 2010-02-20
DK1758886T3 (da) 2015-04-27
IL179905A0 (en) 2007-05-15
US8742099B2 (en) 2014-06-03
US20120202811A1 (en) 2012-08-09
US20070254888A1 (en) 2007-11-01
EP2918580A1 (en) 2015-09-16
US8202864B2 (en) 2012-06-19
PL1758886T3 (pl) 2015-08-31
SI1758886T1 (sl) 2015-06-30
US20140235639A1 (en) 2014-08-21
HK1208669A1 (en) 2016-03-11
US20160030442A1 (en) 2016-02-04
ZA200610022B (en) 2008-07-30
AU2005256470A1 (en) 2006-01-05
US20110152262A1 (en) 2011-06-23
JP5503709B2 (ja) 2014-05-28
CN1972924B (zh) 2011-07-20
HK1106499A1 (en) 2008-03-14
MA28675B1 (fr) 2007-06-01
CA2571527A1 (en) 2006-01-05
NO338769B1 (no) 2016-10-17
PE20060477A1 (es) 2006-08-24
MXPA06014545A (es) 2007-03-12
EP1758886A1 (en) 2007-03-07
GB0414093D0 (en) 2004-07-28
CA2571527C (en) 2013-02-26
US20150157640A1 (en) 2015-06-11
US9408851B2 (en) 2016-08-09
BRPI0512376A (pt) 2008-03-11

Similar Documents

Publication Publication Date Title
US9408851B2 (en) Compounds
AU2004251868B2 (en) Substituted diketopiperazines and their use as oxytocin antagonists
US20070208031A1 (en) Substituted Diketopiperazines as Oxytocin Antagonists
US20070185162A1 (en) Substituted diketopiperazines as oxytocin receptor antagonists
HK1106499B (en) Piperazinediones as oxytocin receptor antagonists
KR20070031952A (ko) 옥시토신 길항제로서 치환된 디케토피페라진

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired